Amaninder Singh Dhillon on LinkedIn: World's first AI hospital opens in China and it can treat 3,000 patients a… (2024)

Courtesy Ambarish Giliyar𝗜̲𝗻̲𝘁̲𝗿̲𝗶̲𝗴̲𝘂̲𝗶̲𝗻̲𝗴̲ ̲𝗖̲𝗼̲𝗺̲𝗽̲𝗮̲𝗿̲𝗶̲𝘀̲𝗼̲𝗻̲ ̲𝗮̲𝗻̲𝗱̲ ̲𝗦̲𝗵̲𝗶̲𝗳̲𝘁̲𝗶̲𝗻̲𝗴̲ ̲𝗟̲𝗮̲𝗻̲𝗱̲𝘀̲𝗰̲𝗮̲𝗽̲𝗲̲Ten to fifteen years ago, the healthcare canvas was primarily composed of a few horizontal and vertical lines focused on manufacturing, distribution, sales, and marketing. The industry operated on a straightforward, transactional model driven by push strategies and conventional sales tactics.Fast forward to today, and the healthcare ecosystem has transformed into a vibrant and intricate tapestry, teeming with digital health innovations, telemedicine, ePharmacies, personalized chronic care solutions, and sophisticated data management technologies. This rapid evolution is a testament to the accelerated integration of technology and the rising consumer demand for convenience, accessibility, and personalized care.🅾🅿🅸🅽🅸🅾🅽 🅾🅽 🆃🅷🅴 🅿🅷🅰🆁🅼🅰 🅶🅰🅼🅴 🅿🅻🅰🅽In this dynamically shifting landscape, the traditional push and transactional tactics are becoming obsolete. Pharma companies must pivot to a more customer-centric approach, emphasizing value, engagement, and outcomes. ₮ⱧɆ ₦Ɇ₩ ₲₳₥Ɇ ₱Ⱡ₳₦ ₴ⱧØɄⱠĐ ł₦₵ⱠɄĐɆ:🅻🅴🆅🅴🆁🅰🅶🅸🅽🅶 🅳🅸🅶🅸🆃🅰🅻 🅷🅴🅰🅻🆃🅷 🅿🅻🅰🆃🅵🅾🆁🅼🆂: Partner with telehealth, ePharmacy, and chronic care platforms to enhance patient engagement and adherence.🅳🅰🆃🅰-🅳🆁🅸🆅🅴🅽 🅳🅴🅲🅸🆂🅸🅾🅽🆂: Utilize advanced analytics to gain insights into patient behavior and treatment outcomes, enabling more personalized and effective interventions.🅲🅾🅻🅻🅰🅱🅾🆁🅰🆃🅸🆅🅴 🅴🅲🅾🆂🆈🆂🆃🅴🅼: Foster collaborations across the digital health spectrum to create integrated and seamless healthcare solutions.🅴🅼🅱🆁🅰🅲🅸🅽🅶 🅳🅸🅶🅸🆃🅰🅻 🆃🅷🅴🆁🅰🅿🅴🆄🆃🅸🅲🆂: Invest in digital therapeutics to provide continuous and customized care, particularly for chronic conditions.🅿🅰🆃🅸🅴🅽🆃-🅲🅴🅽🆃🆁🅸🅲 🅼🅾🅳🅴🅻🆂: Shift from a product-centric to a patient-centric model, prioritizing the patient's journey and experience.C🅛🅞🅢🅘🅝🅖 T🅗🅞🅤🅖🅗🅣🅢In conclusion, the era of push strategies and transactional tactics is fading. Embracing a holistic, technology-driven approach will not only ensure survival but also propel growth in this rapidly evolving healthcare landscape. How ready is your organization to pivot and thrive in this new paradigm?Join link minded pharma professional group- Pharma Strategist and Marketers- Think Tank'https://lnkd.in/g-87vSpaTelegram Links: https://lnkd.in/g3Stq-pF

1

"Did you know that the burden of cancer goes beyond just the disease itself?It's the emotional toll, the financial strain, and the impact on daily life that can be just as debilitating. That's why Novartis' recent campaign, Rethink CML, is so crucial. By shifting the focus from just efficacy to the patient experience, they're acknowledging that it's not just about treating the disease, but about improving the lives of those affected.This shift in approach is a game-changer for the pharma industry. In the future, it's not just about the medicine itself, but about how it makes patients feel, how easy it is to take, and how it fits into their daily routine. It's about the quality of life, the convenience, and the well-being of both patients and caregivers.As we move forward, we can expect to see more campaigns like Rethink CML, where the focus is on the softer metrics that truly matter. It's a reminder that the future of pharma is about more than just treating the disease; it's about transforming lives.Share your own experiences and insights in the comments below. #PatientExperience #PharmaFuture"Angé Weinrabe

1

ASCO 2024 Hɪɢʜʟɪɢʜᴛꜱ ᴀɴᴅ AɴᴀʟʏꜱɪꜱDr. Bishal Gyawali shares his insights on the latest developments at the American Society of Clinical Oncology (ASCO) 2024 conference. Here are the key takeaways from a 𝔻𝕚𝕘𝕚𝕥𝕒𝕝 𝕆𝕡𝕚𝕟𝕚𝕠𝕟 𝕃𝕖𝕒𝕕𝕖𝕣 𝒫𝒶𝓉𝒾ℯ𝓃𝓉-𝒞ℯ𝓃𝓉𝓇𝒾𝒸 𝒯𝓇𝒾𝒶𝓁𝓈- 𝐋𝐀𝐔𝐑𝐀 𝐒𝐭𝐮𝐝𝐲: Osimertinib after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC shows promising results.- 𝐀𝐃𝐑𝐈𝐀𝐓𝐈𝐂 𝐒𝐭𝐮𝐝𝐲: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC) demonstrates efficacy.- 𝐂𝐑𝐎𝐖𝐍 𝐒𝐭𝐮𝐝𝐲: Lorlatinib vs crizotinib in treatment-naive patients with advanced ALK+ non-small cell lung cancer shows 5-year progression-free survival and safety benefits.- 𝐊𝐑𝐘𝐒𝐓𝐀𝐋-𝟏𝟐 𝐒𝐭𝐮𝐝𝐲: Adagrasib vs docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation shows promising results.- 𝐄𝐕𝐎𝐊𝐄-𝟎𝟏 𝐒𝐭𝐮𝐝𝐲: Sacituzumab govitecan vs docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy and PD(L)-1 inhibitors shows efficacy.- 𝐍𝐀𝐃𝐈𝐍𝐀 𝐓𝐫𝐢𝐚: Neoadjuvant nivolumab plus ipilimumab vs adjuvant nivolumab in macroscopic, resectable stage III melanoma demonstrates efficacy.- 𝐄𝐒𝐎𝐏𝐄𝐂 𝐓𝐫𝐢𝐚𝐥: Perioperative chemotherapy (FLOT protocol) vs neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus shows promising results.- 𝐓𝐑𝐀𝐍𝐒𝐌𝐄𝐓 𝐓𝐫𝐢𝐚𝐥: Chemotherapy and liver transplantation vs chemotherapy alone in patients with definitively unresectable colorectal liver metastases demonstrates efficacy.- 𝐃𝐄𝐒𝐓𝐈𝐍𝐘-𝐁𝐫𝐞𝐚𝐬𝐭𝟎𝟔 𝐒𝐭𝐮𝐝𝐲: Trastuzumab deruxtecan vs physician's choice of chemotherapy in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer shows promising results.- 𝐈𝐍𝐀𝐕𝐎𝟏𝟐𝟎 𝐒𝐭𝐮𝐝𝐲: First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer shows efficacy.- 𝐦𝐨𝐧𝐚𝐫𝐜𝐡𝐄 𝐓𝐫𝐢𝐚𝐥: Prognostic utility of ctDNA detection in patients with HR+, HER2-, node-positive, high-risk early breast cancer demonstrates the potential for personalized treatment.Dr. Bishal Gyawali's , Expert Commentary provides critical analysis of the latest developments in oncology, emphasizing the importance of patient-centric trials and personalized medicine.Ⓢⓗⓐⓡⓔ Ⓨⓞⓤⓡ Ⓣⓗⓞⓤⓖⓗⓣⓢ- Leave a comment: What are your thoughts on the latest developments in oncology? How do you see these advancements impacting patient care?Bishal GyawaliAmol Akhadehttps://lnkd.in/gkM7BS_4

10

The AI - Will soon be the Trusted Companion of Oncologist "Imagine a future where AI is the trusted brain extension of oncologists, empowering them to make data-driven decisions for diagnosis and treatment selection"With AI-powered tools, oncologists can analyze vast amounts of data, identify patterns, and predict patient responses to immunotherapy. This not only improves patient outcomes but also reduces costs and streamlines treatment processes.There might NOT be the need of Tumor board meeting in future as AI will double up the role of MDT. For pharma marketers, this means adapting to a new landscape where AI-driven insights are crucial for effective product development and marketing strategies. By leveraging AI to analyze patient data and predict treatment outcomes, pharma companies can optimize their products and services to meet the evolving needs of oncologists and patients.The learning for pharma marketers is clear: AI is no longer a novelty but a critical component of the oncology ecosystem. By embracing AI and its applications, pharma companies can stay ahead of the curve and deliver value to patients, oncologists, and the healthcare system as a whole.Reach out and be a part of professional group Pharma Marketer and Strategist - Think Tank Link - https://lnkd.in/g-87vSpaTelegram Channel - https://lnkd.in/g3Stq-pF

11

3 Comments

Sharing in the general interest of Public Pls set your emergency contact number in your mobile phone. This will be of use in case of any emergency/untoward incident.Prevention is better than cure / repentence

4

1 Comment

India's Digital Healthcare Revolution with Google's AI ToolsIndia is gearing up to revolutionize its healthcare system with Google's AI tools, leveraging the Ayushman Bharat Digital Mission (ABDM). This strategic move could give the Indian government a significant edge in managing medicine procurement and inventory efficiently, potentially disrupting the traditional pharma landscape.What does this mean for the pharma industry?1. Streamlined Procurement: AI-powered inventory management could optimize medicine stock levels, reducing waste and costs.2. Data-Driven Insights: Advanced analytics can help identify trends and patterns in medicine usage, informing more effective marketing strategies.3. Personalized Medicine: AI-assisted diagnosis and treatment regimens could lead to more targeted and effective treatments.What should pharma marketers think about?1. Adapting to AI-driven Insights: Stay ahead of the curve by leveraging AI-generated data to inform marketing decisions.2. Embracing Digital Platforms: Utilize digital channels to engage with healthcare professionals and patients, enhancing brand visibility.3. Focusing on Patient-Centricity: Prioritize patient needs and preferences in product development and marketing strategies.The Future of Pharma is HereIndia's bold move to integrate AI in healthcare could be a game-changer. Stay tuned for more updates on this exciting development and get ready to adapt to the rapidly evolving pharma landscape.𝓒𝓸𝓷𝓷𝓮𝓬𝓽 𝔀𝓲𝓽𝓱 𝓵𝓲𝓴𝓮 𝓶𝓲𝓷𝓭𝓮𝓭 𝓹𝓱𝓪𝓻𝓶𝓪 𝓹𝓻𝓸𝓯𝓮𝓼𝓼𝓲𝓸𝓷𝓪𝓵𝓼 𝓪𝓷𝓭 𝓳𝓸𝓲𝓷 𝓽𝓱𝓮 𝓬𝓸𝓶𝓶𝓾𝓷𝓲𝓽𝔂 𝓸𝓯 𝓟𝓱𝓪𝓻𝓶𝓪 𝓢𝓽𝓻𝓪𝓽𝓮𝓰𝓲𝓼𝓽 𝓪𝓷𝓭 𝓜𝓪𝓻𝓴𝓮𝓽𝓮𝓻𝓼 - 𝓣𝓱𝓲𝓷𝓴 𝓣𝓪𝓷𝓴𝐋𝐢𝐧𝐤 𝐭𝐨 𝐣𝐨𝐢𝐧 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 : https://lnkd.in/g-87vSpa𝐓𝐞𝐥𝐞𝐠𝐫𝐚𝐦 𝐋𝐢𝐧𝐤: https://lnkd.in/g3Stq-pF

15

1 Comment

Tumor immunology simplified Creativity, Visualization, and bit of Humour are core to Pharma Marketing.𝓒𝓸𝓷𝓷𝓮𝓬𝓽 𝔀𝓲𝓽𝓱 𝓵𝓲𝓴𝓮 𝓶𝓲𝓷𝓭𝓮𝓭 𝓹𝓱𝓪𝓻𝓶𝓪 𝓹𝓻𝓸𝓯𝓮𝓼𝓼𝓲𝓸𝓷𝓪𝓵𝓼 𝓪𝓷𝓭 𝓳𝓸𝓲𝓷 𝓽𝓱𝓮 𝓬𝓸𝓶𝓶𝓾𝓷𝓲𝓽𝔂 𝓸𝓯 𝓟𝓱𝓪𝓻𝓶𝓪 𝓢𝓽𝓻𝓪𝓽𝓮𝓰𝓲𝓼𝓽 𝓪𝓷𝓭 𝓜𝓪𝓻𝓴𝓮𝓽𝓮𝓻𝓼 - 𝓣𝓱𝓲𝓷𝓴 𝓣𝓪𝓷𝓴𝐋𝐢𝐧𝐤 𝐭𝐨 𝐣𝐨𝐢𝐧 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 : https://lnkd.in/g-87vSpa𝐓𝐞𝐥𝐞𝐠𝐫𝐚𝐦 𝐋𝐢𝐧𝐤: https://lnkd.in/g3Stq-pF

7

Why so much push back when a model offers all the below. Convenience TimeQuality Cost Subscription serviceAdd on serviceWhy put Regulatory and legal spanner into this?

11

Indian healthcare AI start-up Jivi ranked world’s best Jivi MedX has beaten established LLMs, including OpenAI’s GPT-4 and Google’s Med-PaLM 2 with an average score of 91.65 across the leaderboard’s nine benchmark categories.The evaluation covers medical exams such as Indian medical entrance exams (AIIMS and NEET), US Medical License Exams (USMLE), and detailed assessments in clinical knowledge, medical genetics, and professional medicine, among others.Our mission at Jivi, is to harness artificial intelligence to enhance patient care. The platform accelerates diagnostics and ensures higher accuracy, enabling timely and precise treatment for all

9